Low mortality rates related to respiratory virus infections after bone marrow transplantation
- PMID: 12692610
- PMCID: PMC7091922
- DOI: 10.1038/sj.bmt.1703900
Low mortality rates related to respiratory virus infections after bone marrow transplantation
Abstract
Respiratory viruses (RVs) frequently cause severe respiratory disease in bone marrrow transplant (BMT) recipients. To evaluate the frequency of RV, nasal washes were collected year-round from BMT recipients with symptoms of upper respiratory tract infection (URI). Direct immunofluorescence assay was performed for respiratory syncytial virus (RSV), influenza (Flu) A and B, adenovirus and parainfluenza (Paraflu) virus. Patients with RSV pneumonia or with upper RSV infection, but considered at high risk for developing RSV pneumonia received aerosolized ribavirin. Oseltamivir was given to patients with influenza. A total of 179 patients had 392 episodes of URI. In all, 68 (38%) tested positive: RSV was detected in 18 patients (26.4%), Flu B in 17 (25%), Flu A in 11 (16.2%) and Paraflu in 7 (10.3%). A total of 14 patients (20.6%) had multiple RV infections or coinfection. RSV pneumonia developed in 55.5% of the patients with RSV-URI. One of the 15 patients (6.6%) with RSV pneumonia died. Influenza pneumonia was diagnosed in three patients (7.3%). RSV and influenza infections peaked in fall-winter and winter-spring months, respectively. We observed decreased rates of influenza and parainfluenza pneumonia and low mortality because of RSV pneumonia. The role of antiviral interventions such as aerosolized ribavirin and new neuraminidase inhibitors remains to be defined in randomized trials.
Figures
Similar articles
-
Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections.Bone Marrow Transplant. 1997 May;19(9):905-8. doi: 10.1038/sj.bmt.1700752. Bone Marrow Transplant. 1997. PMID: 9156264
-
Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.Bone Marrow Transplant. 2000 Apr;25(7):751-5. doi: 10.1038/sj.bmt.1702228. Bone Marrow Transplant. 2000. PMID: 10745261 Clinical Trial.
-
Use of Oseltamivir to control influenza complications after bone marrow transplantation.Bone Marrow Transplant. 2004 Jul;34(2):111-4. doi: 10.1038/sj.bmt.1704534. Bone Marrow Transplant. 2004. PMID: 15094755 Clinical Trial.
-
Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host.Semin Respir Infect. 1995 Dec;10(4):224-31. Semin Respir Infect. 1995. PMID: 8668850 Review.
-
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.Clin Infect Dis. 2014 Nov 15;59 Suppl 5(Suppl 5):S344-51. doi: 10.1093/cid/ciu623. Clin Infect Dis. 2014. PMID: 25352629 Free PMC article. Review.
Cited by
-
Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections.J Antimicrob Chemother. 2013 Aug;68(8):1872-80. doi: 10.1093/jac/dkt111. Epub 2013 Apr 9. J Antimicrob Chemother. 2013. PMID: 23572228 Free PMC article.
-
Viral respiratory tract infections in transplant patients: epidemiology, recognition and management.Drugs. 2007;67(10):1411-27. doi: 10.2165/00003495-200767100-00004. Drugs. 2007. PMID: 17600390 Free PMC article. Review.
-
A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infection.J Pediatr Hematol Oncol. 2009 Nov;31(11):825-31. doi: 10.1097/MPH.0b013e3181b7873e. J Pediatr Hematol Oncol. 2009. PMID: 19801951 Free PMC article.
-
[Children with cancer and respiratory viral infection: epidemiology, diagnosis and treatment options].Enferm Infecc Microbiol Clin. 2011 Jan;29(1):40-51. doi: 10.1016/j.eimc.2010.04.011. Epub 2010 Dec 22. Enferm Infecc Microbiol Clin. 2011. PMID: 21183254 Free PMC article. Review. Spanish.
-
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience.Blood Adv. 2021 Feb 9;5(3):861-871. doi: 10.1182/bloodadvances.2020003883. Blood Adv. 2021. PMID: 33560397 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical